Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22367241,plasma levels,"Mean plasma levels (±SD) were 366 ± 173, 0.38 ± 0.09, and 34 ± 12 nM for letrozole, carbinol, and carbinol-gluc, respectively.","Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367241/),,36,6771,DB01006,Letrozole
,22367241,plasma levels,"Mean plasma levels (±SD) were 366 ± 173, 0.38 ± 0.09, and 34 ± 12 nM for letrozole, carbinol, and carbinol-gluc, respectively.","Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367241/),,0.38,6772,DB01006,Letrozole
,22367241,plasma levels,"Mean plasma levels (±SD) were 366 ± 173, 0.38 ± 0.09, and 34 ± 12 nM for letrozole, carbinol, and carbinol-gluc, respectively.","Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367241/),,34,6773,DB01006,Letrozole
,30357450,peak plasma,"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],3-4,7606,DB01006,Letrozole
,30357450,brain tissue letrozole,"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],3-4,7607,DB01006,Letrozole
,30357450,concentrations (Cmax),"In NSG mice, peak plasma and brain tissue letrozole concentrations (Cmax) were 3-4 and 0.8-0.9 µg/ml, respectively.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],0.8-0.9,7608,DB01006,Letrozole
,30357450,elimination half-life,The elimination half-life was 2.6 h with minimal accumulation following multiple dosing.,Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),h,2.6,7609,DB01006,Letrozole
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],14.7,7610,DB01006,Letrozole
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],4.6,7611,DB01006,Letrozole
,30357450,peak plasma,"For instance, peak plasma and brain ECF TMZ levels when given alone were 14.7 ± 1.1 and 4.6 ± 0.6 µg/ml, respectively, and 12.6 ± 2.4 and 3.4 ± 0.8 µg/ml, respectively, when given with letrozole.",Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357450/),[μg] / [ml],12.6,7612,DB01006,Letrozole
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,22,12011,DB01006,Letrozole
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,13,12012,DB01006,Letrozole
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,13.8,12013,DB01006,Letrozole
,30515674,trough concentration,"Although mean palbociclib trough concentration was higher in Japanese patients vs non-Asians (95.4 vs 61.7 ng/mL), the range of individual values of the Japanese patients was within that of non-Asians.","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),[ng] / [ml],95.4,12014,DB01006,Letrozole
,30515674,trough concentration,"Although mean palbociclib trough concentration was higher in Japanese patients vs non-Asians (95.4 vs 61.7 ng/mL), the range of individual values of the Japanese patients was within that of non-Asians.","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),[ng] / [ml],61.7,12015,DB01006,Letrozole
,31223043,bioavailability,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),,11.3,14917,DB01006,Letrozole
,31223043,bioavailability,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),,4.2,14918,DB01006,Letrozole
,31223043,mean residence time,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),h,81.11,14919,DB01006,Letrozole
,31223043,mean residence time,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),h,64.42,14920,DB01006,Letrozole
,31223043,half-life,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),h,51.01,14921,DB01006,Letrozole
,31223043,half-life,In vivo bioavailability studies showed an almost four-fold increase in the plasma concentration (11.3 versus 4.2) while the mean residence time (81.11 versus 64.42 h) and half-life (51.01 versus 39.36 h) were reasonably higher than plain LET cream.,Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31223043/),h,39.36,14922,DB01006,Letrozole
>,24726842,absolute oral bioavailability,Its absolute oral bioavailability was >100%.,VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726842/),%,100,20944,DB01006,Letrozole
,9429742,absolute systemic bioavailability,Letrozole absolute systemic bioavailability after p.o. administration was 99.9 +/- 16.3%.,Absolute bioavailability of letrozole in healthy postmenopausal women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429742/),%,99.9,23363,DB01006,Letrozole
,9429742,Total-body clearance,Total-body clearance of letrozole from plasma after i.v. administration was low (2.21 L h-1).,Absolute bioavailability of letrozole in healthy postmenopausal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429742/),[l] / [h],2.21,23364,DB01006,Letrozole
,9429742,distribution volume at steady state,The calculated distribution volume at steady state (1.87 L kg-1) suggests a rather high tissue distribution.,Absolute bioavailability of letrozole in healthy postmenopausal women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429742/),[l] / [kg],1.87,23365,DB01006,Letrozole
,29345736,steady-,"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[h·ng] / [ml],1979,27950,DB01006,Letrozole
,29345736,area under the plasma concentration-time curve over the dosing interval [τ],"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[h·ng] / [ml],1979,27951,DB01006,Letrozole
,29345736,maximum plasma concentration,"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[ng] / [ml],124.7,27952,DB01006,Letrozole
,29345736,trough concentration,"For day 15 plasma samples from cycles 1 and 2, geometric mean of the within-patient mean trough concentration was 90.1 ng/mL.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[ng] / [ml],90.1,27953,DB01006,Letrozole
,19362193,flow rate,"The chromatographic separation was achieved on C18 column at 35 degrees C, with a mobile phase consisting of water: acetonitrile (adjusted to pH 3.0 with 20% o-phosphoric acid) (60:40), at a flow rate of 1.0 mL min(-1).",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),[ml] / [min],1.0,37128,DB01006,Letrozole
,19362193,retention times,"Bicalutamide and letrozole were well separated with retention times of 10.9+/-0.2 and 5.7+/-0.2 min, respectively.",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),min,10.9,37129,DB01006,Letrozole
,19362193,retention times,"Bicalutamide and letrozole were well separated with retention times of 10.9+/-0.2 and 5.7+/-0.2 min, respectively.",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),min,5.7,37130,DB01006,Letrozole
,9267682,half-life,"However, in view of the half-life of about 2 d this small change in the absorption rate is not considered to be of clinical relevance for treatment with repeated administrations.",Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267682/),d,2,45891,DB01006,Letrozole
,19217534,K(i),"Letrozole (1-[bis-(4-cyanophenyl)methyl]-1H-1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor (K(i)=11.5 nM) that has Food and Drug Administration approval for breast cancer treatment.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),nM,11.5,55244,DB01006,Letrozole
,19217534,specific activity,"[(11)C-cyano]Letrozole was synthesized in 60 min with a radiochemical yield of 79-80%, with a radiochemical purity greater than 98% and a specific activity of 4.16+/-2.21 Ci/mumol at the end of bombardment (n=4).","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),[ci] / [μM],4.16,55245,DB01006,Letrozole
,19217534,free fraction,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),%,48.9,55246,DB01006,Letrozole
,19217534,log D,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),,1.84,55247,DB01006,Letrozole
,27379747,flow rate,The flow rate was 0.5mL/min.,A highly sensitive LC-MS/MS method for determination of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379747/),[ml] / [min],0.5,68987,DB01006,Letrozole
,31125276,trough concentration,Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 v 61.7 ng/mL).,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125276/),[ng] / [ml],93.8,69625,DB01006,Letrozole
,31125276,trough concentration,Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 v 61.7 ng/mL).,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125276/),[ng] / [ml],61.7,69626,DB01006,Letrozole
,33835229,maximum plasma concentration,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng] / [ml],82.14,80001,DB01006,Letrozole
,33835229,maximum plasma concentration,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng] / [ml],139.7,80002,DB01006,Letrozole
,33835229,apparent clearance,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[l] / [h],52.40,80003,DB01006,Letrozole
,33835229,apparent clearance,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[l] / [h],49.97,80004,DB01006,Letrozole
,33835229,AUCτ,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng∙h] / [ml],1217,80005,DB01006,Letrozole
,33835229,AUCτ,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng∙h] / [ml],2501,80006,DB01006,Letrozole
,33835229,t½,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),h,23.46,80007,DB01006,Letrozole
,33835229,t½,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),h,27.26,80008,DB01006,Letrozole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,2.6,80402,DB01006,Letrozole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,7.7,80403,DB01006,Letrozole
,17644287,oral bioavailabilities,"Mean+/-S.D. oral bioavailabilities were 2.6+/-0.4% for raloxifene formulated with microcrystalline cellulose, 7.7+/-2.1% for a solid capsule formulation of raloxifene:HBenBCD complex, and 5.7+/-1.3% for a liquid-filled capsule formulation containing raloxifene:HBenBCD/PEG400/H(2)O.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),%,5.7,80404,DB01006,Letrozole
,17644287,T(max),"Relative to raloxifene/microcrystalline filled capsules, the presence of HBenBCD in the solid capsule formulation afforded: (i) a decrease in raloxifene T(max) (2.5+/-0.5h versus 4.0+/-0.5h); (ii) a two-fold increase in raloxifene C(max) and a three-fold increase in raloxifene AUC; and (iii) a 12-fold increase in raloxifene glucuronide C(max) and a 6.5-fold increase in raloxifene glucuronide AUC.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),h,2.5,80405,DB01006,Letrozole
,17644287,T(max),"Relative to raloxifene/microcrystalline filled capsules, the presence of HBenBCD in the solid capsule formulation afforded: (i) a decrease in raloxifene T(max) (2.5+/-0.5h versus 4.0+/-0.5h); (ii) a two-fold increase in raloxifene C(max) and a three-fold increase in raloxifene AUC; and (iii) a 12-fold increase in raloxifene glucuronide C(max) and a 6.5-fold increase in raloxifene glucuronide AUC.",Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644287/),h,4.0,80406,DB01006,Letrozole
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,17,90896,DB01006,Letrozole
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,8,90897,DB01006,Letrozole
,11501174,terminal phase half-lives (T1/2),"Estimated terminal phase half-lives (T1/2) were 10.5 and 40.4 h, respectively.",Gender difference in letrozole pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),h,10.5,95832,DB01006,Letrozole
,11501174,terminal phase half-lives (T1/2),"Estimated terminal phase half-lives (T1/2) were 10.5 and 40.4 h, respectively.",Gender difference in letrozole pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),h,40.4,95833,DB01006,Letrozole
,11501174,cumulative excreted fractions,"In female rats, cumulative excreted fractions of Letr in urine and feces were 5.8% +/- 1.4% and 6.6% +/- 1.1% within 120 h after administration, respectively, but in male rats, the excreted fractions of Letr in urine and feces were only 1.30% +/- 0.59% and 0.87% +/- 0.31%.",Gender difference in letrozole pharmacokinetics in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),%,5.8,95834,DB01006,Letrozole
,11501174,cumulative excreted fractions,"In female rats, cumulative excreted fractions of Letr in urine and feces were 5.8% +/- 1.4% and 6.6% +/- 1.1% within 120 h after administration, respectively, but in male rats, the excreted fractions of Letr in urine and feces were only 1.30% +/- 0.59% and 0.87% +/- 0.31%.",Gender difference in letrozole pharmacokinetics in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),%,6.6,95835,DB01006,Letrozole
,11501174,excreted fractions,"In female rats, cumulative excreted fractions of Letr in urine and feces were 5.8% +/- 1.4% and 6.6% +/- 1.1% within 120 h after administration, respectively, but in male rats, the excreted fractions of Letr in urine and feces were only 1.30% +/- 0.59% and 0.87% +/- 0.31%.",Gender difference in letrozole pharmacokinetics in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),%,1.30,95836,DB01006,Letrozole
,11501174,excreted fractions,"In female rats, cumulative excreted fractions of Letr in urine and feces were 5.8% +/- 1.4% and 6.6% +/- 1.1% within 120 h after administration, respectively, but in male rats, the excreted fractions of Letr in urine and feces were only 1.30% +/- 0.59% and 0.87% +/- 0.31%.",Gender difference in letrozole pharmacokinetics in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501174/),%,0.87,95837,DB01006,Letrozole
,33798227,plasma AUC 0-24,"At steady state, the plasma AUC 0-24 was 103.0 and 24.8 μg*h/ml and brain ECF AUC 0-12 was 24.0 and 4.8 μg*h/ml in female and male rats, respectively.",Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798227/),[h·μg] / [ml],103.0,105305,DB01006,Letrozole
,33798227,plasma AUC 0-24,"At steady state, the plasma AUC 0-24 was 103.0 and 24.8 μg*h/ml and brain ECF AUC 0-12 was 24.0 and 4.8 μg*h/ml in female and male rats, respectively.",Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798227/),[h·μg] / [ml],24.8,105306,DB01006,Letrozole
,33798227,AUC 0-12,"At steady state, the plasma AUC 0-24 was 103.0 and 24.8 μg*h/ml and brain ECF AUC 0-12 was 24.0 and 4.8 μg*h/ml in female and male rats, respectively.",Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798227/),[h·μg] / [ml],24.0,105307,DB01006,Letrozole
,33798227,AUC 0-12,"At steady state, the plasma AUC 0-24 was 103.0 and 24.8 μg*h/ml and brain ECF AUC 0-12 was 24.0 and 4.8 μg*h/ml in female and male rats, respectively.",Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: Application of physiologically-based pharmacokinetic modeling to gain quantitative insights. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33798227/),[h·μg] / [ml],4.8,105308,DB01006,Letrozole
,16912967,"terminal half-lives (t(1/2,lambdaz))","The plasma concentration-time profiles of letrozole (0.1-2.0 mg/kg) after single i.v. doses were analysed by the non-compartment model with terminal half-lives (t(1/2,lambdaz)) ranging from 34.3 to 37.5 h.",The effect of tamoxifen on the pharmacokinetics of letrozole in female rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912967/),h,34.3 to 37.5,129216,DB01006,Letrozole
,16912967,volume of distribution at the terminal phases (Vd(lambdaz)),The volume of distribution at the terminal phases (Vd(lambdaz)) ranged from 1.9 to 2.1 l/kg and clearance (CL) varied from 0.036 to 0.042 l/(h.kg).,The effect of tamoxifen on the pharmacokinetics of letrozole in female rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912967/),[l] / [kg],1.9 to 2.1,129217,DB01006,Letrozole
,16912967,clearance (CL),The volume of distribution at the terminal phases (Vd(lambdaz)) ranged from 1.9 to 2.1 l/kg and clearance (CL) varied from 0.036 to 0.042 l/(h.kg).,The effect of tamoxifen on the pharmacokinetics of letrozole in female rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912967/),[l] / [h·kg],0.036 to 0.042,129218,DB01006,Letrozole
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],1322,134320,DB01006,Letrozole
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],547.5,134321,DB01006,Letrozole
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],2838,134322,DB01006,Letrozole
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],1276,134323,DB01006,Letrozole
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],104.1,134324,DB01006,Letrozole
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],41.4,134325,DB01006,Letrozole
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],185.5,134326,DB01006,Letrozole
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],77.4,134327,DB01006,Letrozole
,26991823,Half-life,Half-life was 23-26 h.,"Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),h,23-26,134328,DB01006,Letrozole
,10430063,time to disease progression,"Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months.",Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430063/),month,7.6,135153,DB01006,Letrozole
,23264941,flow rate,"The analysis was carried out on a reversed-phase C18 (250 mm × 4.6 mm, 5 μm) column with an isocratic mobile phase of methanol-water (70:30,v/v), at a flow rate of 1.0 mL min(-1).",Development of a high-performance liquid chromatographic method for determination of letrozole in wistar rat serum and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264941/),[ml] / [min],1.0,176960,DB01006,Letrozole
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),h,41-48,186734,DB01006,Letrozole
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,2-4,186735,DB01006,Letrozole
,12538502,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) are 41-48 h, 2-4 days, and 27 h, respectively.",Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),h,27,186736,DB01006,Letrozole
,12538502,Time to steady-state plasma levels,Time to steady-state plasma levels is 7 days for both anastrozole and exemestane and 60 days for letrozole.,Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,7,186737,DB01006,Letrozole
,12538502,Time to steady-state plasma levels,Time to steady-state plasma levels is 7 days for both anastrozole and exemestane and 60 days for letrozole.,Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538502/),d,60,186738,DB01006,Letrozole
,21494765,CL/F,CL/F in subjects possessing 1 and 2 CYP2A6 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively.,Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21494765/),%,84,190721,DB01006,Letrozole
,21494765,CL/F,CL/F in subjects possessing 1 and 2 CYP2A6 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively.,Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21494765/),%,44,190722,DB01006,Letrozole
,9081401,objective response rate,"One patient achieved a complete response (CR) and 4 patients a partial response (PR), with an objective response rate of 36% (95% CI 13% to 65%).","Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081401/),%,36,202460,DB01006,Letrozole
,9081401,duration of response,"Median duration of response was 24 months, ranging from 4 to 44 months.","Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081401/),month,24,202461,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],93.5,234977,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],86.5,234978,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],91.1,234979,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],89.6,234980,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],29.1,234981,DB01006,Letrozole
,23596562,Trough concentrations,"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng/mL; p=0.97).",Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23596562/),[ng] / [ml],29.1,234982,DB01006,Letrozole
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),h,41-48,240675,DB01006,Letrozole
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,2-4,240676,DB01006,Letrozole
,12404296,plasma half-lives,"At clinically administered doses, the plasma half-lives of anastrozole (1 mg once daily), letrozole (2.5 mg once daily), and exemestane (25 mg once daily) were 41-48 hours, 2-4 days, and 27 hours, respectively.","An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),h,27,240677,DB01006,Letrozole
,12404296,time to steady-state plasma levels,The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole.,"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,7,240678,DB01006,Letrozole
,12404296,time to steady-state plasma levels,The time to steady-state plasma levels was 7 days for both anastrozole and exemestane and 60 days for letrozole.,"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404296/),d,60,240679,DB01006,Letrozole
,26851241,IC50,IC50 values from recombinant enzymes indicated that an interaction is most probable for CYP2A6 (IC50 = 6.1 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,6.1,242385,DB01006,Letrozole
,26851241,KS,t-CA is a type I ligand for CYP2A6 (KS = 14.9 µM).,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,14.9,242386,DB01006,Letrozole
,26851241,K(I),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),μM,18.0,242387,DB01006,Letrozole
,26851241,k(inact),"Using a static model and mechanism-based inhibition parameters (K(I) = 18.0 µM; k(inact) = 0.056 minute(-1)), changes in the area under the concentration-time curve (AUC) for nicotine and letrozole were predicted in the presence of t-CA (0.1 and 1 µM).",Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),1/[minute],0.056,242388,DB01006,Letrozole
,26851241,AUC fold-change,The AUC fold-change ranged from 1.1 to 3.6.,Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26851241/),,1.1,242389,DB01006,Letrozole
,16361559,area under the plasma concentration versus time curve (AUC),"There was no significant effect of exemestane on the area under the plasma concentration versus time curve (AUC) of tamoxifen at steady state before [3.04 mg h/L; 90% confidence interval (90% CI), 2.71-3.44] and during exemestane treatment (3.05 mg h/L; 90% CI, 2.72-3.41).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·mg] / [l],3.04,243415,DB01006,Letrozole
,16361559,area under the plasma concentration versus time curve (AUC),"There was no significant effect of exemestane on the area under the plasma concentration versus time curve (AUC) of tamoxifen at steady state before [3.04 mg h/L; 90% confidence interval (90% CI), 2.71-3.44] and during exemestane treatment (3.05 mg h/L; 90% CI, 2.72-3.41).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·mg] / [l],3.05,243416,DB01006,Letrozole
,16361559,Oral clearance,"Oral clearance of exemestane averaged 602 L/h based on an average plasma exemestane AUC of 41.5 microg h/L (90% CI, 36.7-62.6).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[l] / [h],602,243417,DB01006,Letrozole
,16361559,AUC,"Oral clearance of exemestane averaged 602 L/h based on an average plasma exemestane AUC of 41.5 microg h/L (90% CI, 36.7-62.6).",Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16361559/),[h·μg] / [l],41.5,243418,DB01006,Letrozole
,17637172,terminal half-life (t(1/2)),"For example, the terminal half-life (t(1/2)) of letrozole following intravenous administration in male rats was 11.5 +/- 1.8 h (n = 3), while in female rats it was 42.3 +/- 2.9 h (n = 3).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),h,11.5,246739,DB01006,Letrozole
,17637172,terminal half-life (t(1/2)),"For example, the terminal half-life (t(1/2)) of letrozole following intravenous administration in male rats was 11.5 +/- 1.8 h (n = 3), while in female rats it was 42.3 +/- 2.9 h (n = 3).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),h,42.3,246740,DB01006,Letrozole
,17637172,C(max),"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),%,61,246741,DB01006,Letrozole
,17637172,C(max),"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),%,42,246742,DB01006,Letrozole
,17637172,T(max),"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),h,8.4 to 6.3,246743,DB01006,Letrozole
,17637172,T(max),"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),h,16.4,246744,DB01006,Letrozole
,17637172,T(max),"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),h,5.4,246745,DB01006,Letrozole
,17637172,absolute oral bioavailability,"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),,46,246746,DB01006,Letrozole
,17637172,absolute oral bioavailability,"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),,38,246747,DB01006,Letrozole
,17637172,absolute oral bioavailability,"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),,101,246748,DB01006,Letrozole
,17637172,absolute oral bioavailability,"When administered in a capsule formulation with letrozole, HBenbetaCD resulted in a higher C(max) (61% in male rats, 42% in female), shorter T(max) values (8.4 to 6.3 h in male, 16.4 h to 5.4 h in female) and increased absolute oral bioavailability (46 +/- 2 vs 38 +/- 3 in male, 101 +/- 3 vs 95 +/- 2 in female).",Pharmacokinetics of letrozole in male and female rats: influence of complexation with hydroxybutenyl-beta cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17637172/),,95,246749,DB01006,Letrozole
,17851757,Objective response rate,Objective response rate was 30% (95% CI; 20-41%) for TL and 38% (95% CI; 23-55%) for L.,"A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851757/),%,30,252453,DB01006,Letrozole
,17851757,Objective response rate,Objective response rate was 30% (95% CI; 20-41%) for TL and 38% (95% CI; 23-55%) for L.,"A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851757/),%,38,252454,DB01006,Letrozole
,17851757,Clinical benefit rates,Clinical benefit rates were 49% (TL) and 62% (L).,"A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851757/),%,49,252455,DB01006,Letrozole
,17851757,Clinical benefit rates,Clinical benefit rates were 49% (TL) and 62% (L).,"A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851757/),%,62,252456,DB01006,Letrozole
